Albireo Pharma, Inc.: Reimbursed Access to Bylvay (odevixibat) Approved in France for Patients with PFIC 1 & 2
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced
Source: finanznachrichten.de